RecruitingPhase 1NCT05773001
Macrophage Regulation of Ozone-Induced Lung Inflammation
Sponsor
Robert Tighe, MD
Enrollment
100 participants
Start Date
May 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria6
- Individuals between 18-55 yrs. of age (No subject will be excluded from the study on the basis of gender or ethnicity)
- Individuals with knowledge of prior respiratory viral infection history allowing them to be segregated into one of three cohorts
- Cohort 1 - No history of respiratory viral infection (defined as no symptoms consistent with respiratory viral infection nor history of a positive respiratory viral test)
- Cohort 2 - Documented mild respiratory viral infection (a positive test, either PCR- or antigen-based) but with mild to no symptoms and no evidence of a lower respiratory tract infection (including no hospitalization, and no oxygen use)
- Cohort 3 - History of respiratory viral infection and symptoms/imaging consistent with a lower respiratory tract infection who have recovered, are >6 months out from their infection, and have normal lung function (spirometry with FVC, FEV1 and FEV1/FVC)
- There will be no maximal period from respiratory viral infection for inclusion in the study, the minimal period will be >6 months out from infection
Exclusion Criteria9
- Individuals with prior respiratory viral pneumonia who have ongoing respiratory symptoms, are still using supplemental oxygen, or have abnormal lung function
- Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years
- Pregnant women and women who are presently lactating.
- Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks
- College and graduate students or employees who are under direct supervision by any of the investigators in this protocol
- Alcohol or illicit substance abuse
- Chronic cardio/pulmonary respiratory disorders or other medical conditions as determined by the investigator
- Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 < 4 mg/ml)
- Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOzone
Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05773001
Related Trials
Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department
NCT076014121 location
Dime La VerDAD: Verify, Debunk, and Disseminate
NCT064177624 locations
Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza
NCT073570511 location
Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza
NCT070952572 locations
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
NCT0555029827 locations